Day: November 10, 2023

Innofactor Plc: Share Repurchase 10.11.2023

Written by Customer Service on November 10, 2023. Posted in Public Companies.

Innofactor Plc Announcement 10.11.2023 Innofactor Plc: Share Repurchase 10.11.2023 In the Helsinki Stock Exchange Trade date 10.11.2023 Bourse trade Buy Share IFA1V Amount 10,000 SharesAverage price/ share 1.0900 EURTotal cost 10,900.00 EUR Innofactor Plc now holds a total of 451 889 sharesincluding the shares repurchased on 10.11.2023 On behalf of Innofactor Plc Nordea Bank Oyj Janne Sarvikivi Sami Huttunen Additional information: Sami Ensio, CEO Innofactor Plc Tel. +358 50 584 2029 sami.ensio@innofactor.com www.innofactor.com AttachmentInnofactor_10.11_trades

Block Listing Six Monthly Return

Written by Customer Service on November 10, 2023. Posted in Public Companies.

TORONTO, ONTARIO, Nov. 10, 2023 (GLOBE NEWSWIRE) — (“Amaroq” or the “Company”) Block Listing Six Monthly Return TORONTO, ONTARIO – November 10, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ First North: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in South Greenland, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies, regarding its existing block admission arrangements in connection with the Amaroq Minerals Stock Option Plan.Name of applicant: Amaroq Minerals LtdName of scheme: Amaroq Minerals ltd. Stock Option PlanPeriod of return: From: 18 May 2023 To: 10 November 2023Balance of unallotted securities under scheme(s) from previous return: 10,559,120Plus: The amount by which the block scheme(s) has...

Alliance Entertainment Reports First Quarter Fiscal Year 2024 Financial Results

Written by Customer Service on November 10, 2023. Posted in Earnings Releases And Operating Results.

First Quarter FY 2024 Net Revenues Totaled $226.8 Million Increasing Business Segment Stabilization Driven by Higher Average Selling Prices and Decreased Operating Expenses Q1 FY 2024 Gross Profit Up 3% to $26.3 Million on Profitable Sales Strategy Q1 FY 2024 Positive Adjusted EBITDA of $1.3 Million PLANTATION, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) — Alliance Entertainment Holding Corporation (Nasdaq: AENT) (“Alliance Entertainment”, “Company”), a distributor and wholesaler of the world’s largest in stock selection of music, movies, video games, electronics, arcades, toys and collectibles, has reported its financial and operational results for the fiscal first quarter ended September 30, 2023. First Quarter and Subsequent 2023 Operational HighlightsSigned a letter of intent (LOI) with White Oak Commercial Finance to secure three-year...

Advantage Solutions named Corporate Champion by the Women’s Forum of New York

Written by Customer Service on November 10, 2023. Posted in Public Companies.

Distinction was awarded to honor gender diversity of Advantage’s board of directors IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) — Advantage Solutions Inc. (NASDAQ: ADV), a leading provider of sales and marketing services to consumer goods manufacturers and retailers, today announced that it has been named a “Corporate Champion” by the Women’s Forum of New York. The recognition is given to publicly traded companies with a board of directors that is composed of at least 40% women. This year, the group is honoring 233 S&P 500 and Fortune 1000 companies for reaching or surpassing that threshold. “At Advantage, ensuring we have diverse perspectives, backgrounds and experiences is at the heart of the company’s culture, and is a critical factor in our company’s success,” said Dave Peacock, CEO of Advantage Solutions. “Our commitment...

STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara

Written by Customer Service on November 10, 2023. Posted in Public Companies.

CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatology Positive CHMP opinion for Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical and clinical similarity data, including AVT04-GL-301 study for pharmacokinetic similarity in healthy subjects and confirmatory comparative efficacy and safety clinical trial in patients with moderate to severe chronic plaque-type psoriasis The market entry of an approved biosimilar into the approximately €2.5 billion EU ustekinumab market could significantly expand patient access via competitionPartners STADA and Alvotech today announced that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency’s (EMA) has adopted a positive...

Bigbank’s Financial Results for October 2023

Written by Customer Service on November 10, 2023. Posted in Public Companies.

October 2023 results were good for Bigbank. Both the deposit portfolio and the loan portfolio grew. In deposits, growth came from the savings deposit portfolio, the volume of which exceeded the 900-million-euro mark in October. In addition to the historically strong Dutch, German and Austrian markets, Estonian and Finnish markets, where Bigbank started offering savings deposits in 2023, have made a significant contribution to this. The volume of term deposits remained essentially at the same level in October, also at EUR 900 million. Bigbank continues to keep deposit rates at the top of the market, which allows Bigbank’s deposit customers to increasingly benefit from the rising interest rate environment. In terms of loans, the portfolio of business loans remained at the same level compared to the end of September. Growth figures...

STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara

Written by Customer Service on November 10, 2023. Posted in Public Companies.

CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatology Positive CHMP opinion for Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical and clinical similarity data, including AVT04-GL-301 study for pharmacokinetic similarity in healthy subjects and confirmatory comparative efficacy and safety clinical trial in patients with moderate to severe chronic plaque-type psoriasis The market entry of an approved biosimilar into the approximately €2.5 billion EU ustekinumab market could significantly expand patient access via competitionBAD VILBEL, Germany and REYKJAVIK, Iceland, Nov. 10, 2023 (GLOBE NEWSWIRE) — Partners STADA and Alvotech today announced that the Committee for Medicinal Products for...

CNL STRATEGIC CAPITAL ANNOUNCES OPERATING RESULTS FOR THIRD QUARTER 2023

Written by Customer Service on November 10, 2023. Posted in Earnings Releases And Operating Results.

Orlando, Fla., Nov. 10, 2023 (GLOBE NEWSWIRE) — CNL Strategic Capital, LLC (“CNL Strategic Capital,” the “Company” or “we”) seeks to provide current income and long-term appreciation to investors by acquiring controlling equity stakes in combination with loan positions in privately owned middle-market businesses. The Company announced its operating results for the nine months ended Sept. 30, 2023. Highlights:As of Sept. 30, 2023, CNL Strategic Capital’s portfolio consisted of equity and debt investments in 12 portfolio companies and approximately $948.8 million in total assets, compared with approximately $732.5 million as of Dec. 31, 2022. For the nine months ended Sept. 30, 2023, the Company recognized a net change in unrealized appreciation on investments of approximately $24.6 million and had total investment income of approximately...

Potentially Material Transactions; Earlier and Staggered Settlement of GIG Public Warrants

Written by Customer Service on November 10, 2023. Posted in Public Companies.

A Press Release including Potentially Material Transactions; Earlier and Staggered Settlement of GIG Public Warrants is attached hereto. Attachment20231110 GIG – Press Release Settlement of Warrant Early Exercise – FINAL

James River Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Written by Customer Service on November 10, 2023. Posted in Public Companies.

PEMBROKE, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) — James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR) today announced that its board of directors has initiated an exploration of strategic alternatives. As part of this process, the board will consider a wide range of options for the Company including, among other things, a potential sale, merger or other strategic transaction. “Over the past three years, James River’s executive leadership team and board of directors have taken decisive actions to focus resources on core businesses where we have meaningful scale, de-risk the organization, reduce volatility and meaningfully strengthen the balance sheet,” said Ollie Sherman, chairman of the board of directors. “The board now believes it is appropriate to explore a range of potential strategic alternatives...

Day: November 10, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals